硫唑嘌呤致胆管消失综合征:早期评估硫嘌呤代谢的价值
约15%至28%接受硫嘌呤治疗的患者出现血液学与肝脏毒性等不良反应,部分与硫嘌呤S-甲基转移酶(TPMT)多态性活性相关。本文报告一例34岁女性系统性红斑狼疮患者,应用硫唑嘌呤后转氨酶由肝细胞型演变为胆汁淤积型,血硫嘌呤代谢物示6-TGN低、6-MMPN显著升高、[6-MMPN:6-TGN]比值不利且TPMT活性高,约6个月后肝活检示胆管消失,停药后临床改善。
要点
- 硫唑嘌呤可致罕见胆管消失综合征,机制未明,可能与6-MMPN血浓度高(代谢转换)有关。
- 血6-TGN低、6-MMPN显著升高及不利的[6-MMPN:6-TGN]比值、TPMT活性高或提示风险。
- 早期治疗药物监测测定6-TGN与6-MMPN血浓度可能帮助识别胆管损伤风险患者。
核心结论
- 硫唑嘌呤所致胆管消失综合征为罕见不良反应,机制未明,可能涉及代谢转换导致的高6-MMPN血浓度。
- 早期治疗药物监测测定6-TGN与6-MMPN血浓度可能帮助医生识别类似胆管损伤风险患者。
研究设计与样本
- 个案报告:一例34岁女性,有严重系统性红斑狼疮病史,近期开始硫唑嘌呤治疗。
- 对硫嘌呤代谢进行了全面药理学分析,包括血硫嘌呤代谢物检测与经颈静脉肝活检。
主要发现
- 患者起病时为轻度波动的转氨酶升高,呈肝细胞型,随后数周演变为胆汁淤积型。
- 血硫嘌呤代谢物检测示6-TGN水平低、6-MMPN水平显著升高,并伴不利的[6-MMPN:6-TGN]比值及高TPMT活性。
- 硫嘌呤治疗共约6个月后经颈静脉肝活检示胆管消失,停用硫唑嘌呤后临床进一步改善。
关键数值与推荐
- 约15%至28%接受硫嘌呤治疗的患者出现血液学与肝脏毒性等不良反应。
- 部分不良反应与硫嘌呤S-甲基转移酶(TPMT)多态性活性相关,该酶为硫嘌呤代谢的关键解毒酶。
- 本病例血6-TGN水平低、6-MMPN水平显著升高,[6-MMPN:6-TGN]比值不利,TPMT活性高。
临床怎么用
- 应用硫唑嘌呤期间出现转氨酶由肝细胞型向胆汁淤积型演变时,应警惕胆管损伤可能。
- 可考虑早期治疗药物监测,检测6-TGN与6-MMPN血浓度以识别代谢异常及胆管损伤风险患者。
- 怀疑硫唑嘌呤相关胆管消失时,停药后需随访临床改善情况。
局限性
- 本文为单个病例报告,结论外推需谨慎。
- 胆管消失综合征作为硫唑嘌呤不良反应的机制尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
About 15% to 28% of patients treated with thiopurines experienced adverse drug reactions, such as haematological and hepatic toxicities. Some of these related to the polymorphic activity of the thiopurine S-methyltransferase (TPMT), the key detoxifying enzyme of thiopurine metabolism. We report here a case of thiopurine-induced ductopenia with a comprehensive pharmacological analysis on thiopurine metabolism. A 34-year-old woman, with a medical history of severe systemic lupus erythematosus with recent introduction of azathioprine therapy, presented with mild fluctuating transaminase blood levels consistent with a hepatocellular pattern, which evolved to a cholestatic pattern over the next weeks. A blood thiopurine metabolite assay revealed low 6-thioguanine nucleotides (6-TGN) level and a dramatically increased 6-methylmercaptopurine ribonucleotides (6-MMPN) level, together with an unfavourable [6-MMPN:6-TGN] metabolite ratio and a high TPMT activity. After a total of about 6 months of thiopurine therapy, a transjugular liver biopsy revealed a ductopenia, and azathioprine discontinuation led to further clinical improvement. In line with previous reports from the literature, our case supports the fact that ductopenia is a rare adverse drug reaction of azathioprine. The mechanism of reaction is unknown but may involve high 6-MMPN blood level, due to unusual thiopurine metabolism (switched metabolism). Early therapeutic drug monitoring with measurement of 6-TGN and 6-MMPN blood levels may help physicians to identify patients at risk of similar duct injury.
引用
- Chouchana L, Terris B, Sogni P, et al. Azathioprine-induced vanishing bile duct syndrome: The value of early thiopurine metabolism assessment. Br J Clin Pharmacol. 2023. PMID: 37218386. doi:10.1111/bcp.15797
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。